Incyte stock climbs after a $130 target raise
Published on 08/18/2026 at 21:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Incyte Corporation (US45337C1027) stock is drawing attention after Piper Sandler lifted its target to $130 from $110 on August 17, 2026, while the shares finished at $123.50 on August 17, 2026 and the company's market value stood at $24.36 billion.
The latest reported quarter adds a second hard number set: revenue reached $1.67 billion, up 37.7% year over year, and adjusted EPS came in at $3.09, above the $2.15 consensus estimate by $0.94.
Analyst support
The target increase leaves the new goal 5.3% above the last close, a modest gap after a strong earnings run. Consensus on the stock still points to an average target of $125.17, which sits only a step above the last quote and below the new $130 mark.
Quarterly momentum
In the same quarter, net margin reached 27.71% and return on equity was 29.93%, giving the rally a profit backdrop rather than a purely sentiment-driven one. Revenue growth of 37.7% year over year is the clearest comparison in the set and shows why the latest results still matter for valuation.
Recent market data also showed 2,040,676 shares traded and a 52-week range of $81.09 to $132.60 as of August 17, 2026, leaving the stock in the upper half of its yearly band.
Opzelura focus
One product that remains central to the business is Opzelura, the topical JAK inhibitor that helped frame the company's latest revenue outlook after the CMS settlement, according to recent market coverage.
Shares and valuation
Incyte stock traded at $123.50 on August 17, 2026, with post-market quotes at $123.98. That places the shares close to the consensus range and still below the 52-week high of $132.60.
Fact box
Company: Incyte Corporation
ISIN: US45337C1027
Ticker: INCY
Exchange: Nasdaq
Price (as of August 17, 2026, 4:00 p.m. ET): $123.50 USD
Market cap: $24.36 billion
Sector / Industry: Health Care / Biotechnology
Index membership: Nasdaq-100
More on Incyte stock
Incyte's revenue base is anchored by oncology and inflammation therapies, with Opzelura now tied to the latest outlook update and the current earnings cadence.
